Observational studyAnnals of internal medicine2023
Demonstration Project of Long-Acting Antiretroviral Therapy in a Diverse Population of People With HIV.
Observational study in Annals of internal medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
77 citing papers in PubMed, 3 syntheses or guidelines pooled it, 100 citations in OpenAlex.
- Pooled it
- Virologic Failure and Emergent Integrase Strand Transfer Inhibitor Drug Resistance With Long-Acting Cabotegravir for HIV Treatment: A Meta-analysis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Pooled it
- Pooled it
- Lenacapavir Use in France: A National, Observational Study (LENAddOn).Open forum infectious diseases · 2026Trial
- The COMEBACK Study: Social Determinants of Health Impact on Virologic Suppression in a 48-Week Low-Barrier-Care Study of Rapid Antiretroviral Therapy Reinitiation Among Persons With HIV Lost to Care.Open forum infectious diseases · 2026Trial
- Lenacapavir Plus Cabotegravir as Combination Treatment: Real-world Use Cases From the National Clinician Consultation Center.Open forum infectious diseases · 2025Trial
- Trial
- Early Experience and Effectiveness of Long-Acting Injectable Cabotegravir and Rilpivirine in a South Side Chicago HIV Clinic.Open forum infectious diseases · 2025Trial
- Neighborhood Resources Indirectly Linked to HIV Medication Adherence Through Social Determinants of Health Among Digitally Surveyed Partnered Men Who Have Sex with Men.AIDS and behavior · 2026Article
- Long-Acting Cabotegravir/Rilpivirine Reduces Immune-Activation and -Senescence in People With HIV With CMV Co-Infection.Immunology · 2026Article
- Impact of implementation process on long-acting cabotegravir/rilpivirine prescription at 9 HIV clinics, 2021-2024.Journal of acquired immune deficiency syndromes (1999) · 2026Article
- Accelerating Low-Barrier Use of Long-Acting Antiretroviral Therapy to Maximize Impact in People with HIV and Viremia or Adherence Challenges.Current HIV/AIDS reports · 2026Review
- Determinants of long-acting cabotegravir plus rilpivirine discontinuation in real-world HIV care: insights from the relativity cohort.AIDS (London, England) · 2026Article
- Long-Acting Antiretroviral Therapy for HIV via Drop-in Community-Based Care.JAMA network open · 2026Article
- Trends in HIV Viral Suppression in the POP-UP Low-Barrier Care Program for People With HIV Experiencing Homelessness or Unstable Housing.Open forum infectious diseases · 2026Article
- Homelessness and HIV Treatment Among Men Who Have Sex With Men Across US Funding Contexts.JAMA network open · 2026Article
- Real-world adherence, persistence, and health care resource utilization among people with HIV receiving long-acting cabotegravir plus rilpivirine compared with oral antiretroviral therapy in the United States: The ABOVE Study.Journal of managed care & specialty pharmacy · 2026Article
- Long-Acting Cabotegravir/Rilpivirine, Lenacapavir, and Ibalizumab Use Among Persons With HIV-1 Viremia at a Ryan White-Funded Clinic in the Urban US South.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Effectiveness and Persistence of Long-Acting Injectable Cabotegravir and Rilpivirine in Migrant Individuals Living With HIV in Spain: Substudy of the RELATIVITY Cohort.Journal of the International AIDS Society · 2026Observational
- Associations Between Sustained Methamphetamine/Amphetamine Use and Left Ventricular Dysfunction in a Cohort of Women Living With and Without HIV.Journal of the American Heart Association · 2026Article
17 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
15 authors at 1 institution in 1 country.
Funding
Abstract
backgroundIntramuscular cabotegravir (CAB) and rilpivirine (RPV) is the only long-acting antiretroviral therapy (LA-ART) regimen approved for people with HIV (PWH). Long-acting ART holds promise for improving outcomes among populations with barriers to adherence but is only approved for PWH who have virologic suppression with use of oral ART before initiating injectables.
objectiveTo examine LA-ART in a population of PWH that includes those with viremia.
designObservational cohort study.
settingUrban academic safety-net HIV clinic. PATIENTS: Publicly insured adults living with HIV with and without viral suppression, high rates of unstable housing, mental illness, and substance use.
interventionDemonstration project of long-acting injectable CAB-RPV. MEASUREMENTS: Descriptive statistics summarizing cohort outcomes to date, based on pharmacy team logs and electronic medical record data.
resultsBetween June 2021 and November 2022, 133 PWH at the Ward 86 HIV Clinic were started on LA-ART, 76 of whom had virologic suppression while using oral ART and 57 of whom had viremia. The median age was 46 years (IQR, 25 to 68 years); 117 (88%) were cisgender men, 83 (62%) had non-White race, 56 (42%) were experiencing unstable housing or homelessness, and 45 (34%) had substance use. Among those with virologic suppression, 100% (95% CI, 94% to 100%) maintained suppression. Among PWH with viremia, at a median of 33 days, 54 of 57 had viral suppression, 1 showed the expected 2-log LIMITATION: Single-site study.
conclusionThis project demonstrates the ability of LA-ART to achieve virologic suppression among PWH, including those with viremia and challenges to adherence. Further data on the ability of LA-ART to achieve viral suppression in people with barriers to adherence are needed. PRIMARY FUNDING SOURCE: National Institutes of Health, City and County of San Francisco, and Health Resources and Services Administration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.